3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Head & Neck
4
Gynecologic
3
Gastrointestinal
3
Dermatologic
3
Other hematologic neoplasm
2
Genitourinary
2
Breast
2
Other
1
Conditions
Hematologic Neoplasms
2
Stomatitis
1
Mucositis
1
Head and Neck Neoplasms
1
Cancer Pain
1
Interventions
Cytarabine
465
Cyclophosphamide
459
fludarabine phosphate
277
Rituximab
249
Methotrexate
245
Etoposide
203
fludarabine
200
Filgrastim
199
Peripheral Blood Stem Cell Transplantation
180
Busulfan
169
Vincristine
163
Dexamethasone
153
Daunorubicin
151
Azacitidine
145
Mycophenolic Acid
142
Whole-Body Irradiation
133
Tacrolimus
127
Imatinib Mesylate
127
Cyclosporine
123
Granulocyte Colony-Stimulating Factor
118
Radiotherapy
113
Melphalan
110
Idarubicin
103
Doxorubicin
101
Mitoxantrone
97
Decitabine
97
Antilymphocyte Serum
97
Lenalidomide
96
Mercaptopurine
93
Prednisone
91
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Completed
×
Laser Therapy
×
Other hematologic neoplasm
×
Clear all
NCT07069153
2025-11-17
LOMUC
University of Pavia
Phase NA
Completed
40 enrolled
NCT02696408
2020-01-29
STOP MUCITES
Institut de Cancérologie de la Loire
Phase 3
Completed
234 enrolled